18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Impacts of dialysis adequacy and intradialytic hypotension on changes in dialysis recovery time

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Dialysis recovery time (DRT) surveys capture the perceived time after HD to return to performing regular activities. Prior studies suggest the majority of HD patients report a DRT > 2 h. However, the profiles of and modifiable dialysis practices associated with changes in DRT relative to the start of dialysis are unknown. We hypothesized hemodialysis (HD) dose and rates of intradialytic hypotension (IDH) would associate with changes in DRT in the first years after initiating dialysis.

          Methods

          We analyzed data from adult HD patients who responded to a DRT survey ≤180 days from first date of dialysis (FDD) during 2014 to 2017. DRT survey was administered with annual KDQOL survey. DRT survey asks: “How long does it take you to be able to return to your normal activities after your dialysis treatment?” Answers are: < 0.5, 0.5-to-1, 1-to-2, 2-to-4, or > 4 h. An adjusted logistic regression model computed odds ratio for a change to a longer DRT (increase above DRT > 2 h) in reference to a change to a shorter DRT (decrease below DRT < 2 h, or from DRT > 4 h). Changes in DRT were calculated from incident (≤180 days FDD) to first prevalent (> 365-to- ≤ 545 days FDD) and second prevalent (> 730-to- ≤ 910 days FDD) years.

          Results

          Among 98,616 incident HD patients (age 62.6 ± 14.4 years, 57.8% male) who responded to DRT survey, a higher spKt/V in the incident period was associated with 13.5% (OR = 0.865; 95%CI 0.801-to-0.935) lower risk of a change to a longer DRT in the first-prevalent year. A higher number of HD treatments with IDH episodes per month in the incident period was associated with a 0.8% (OR = 1.008; 95%CI 1.001-to-1.015) and 1.6% (OR = 1.016; 95%CI 1.006-to-1.027) higher probability of a change to a longer DRT in the first- and second-prevalent years, respectively. Consistently, an increased in incidence of IDH episodes/months was associated to a change to a longer DRT over time.

          Conclusions

          Incident patients who had higher spKt/V and less sessions with IDH episodes had a lower likelihood of changing to a longer DRT in first year of HD. Dose optimization strategies with cardiac stability in fluid removal should be tested.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12882-020-02187-9.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Does obesity shorten life? The importance of well-defined interventions to answer causal questions.

          Many observational studies have estimated a strong effect of obesity on mortality. In this paper, we explicitly define the causal question that is asked by these studies and discuss the problems associated with it. We argue that observational studies of obesity and mortality violate the condition of consistency of counterfactual (potential) outcomes, a necessary condition for meaningful causal inference, because (1) they do not explicitly specify the interventions on body mass index (BMI) that are being compared and (2) different methods to modify BMI may lead to different counterfactual mortality outcomes, even if they lead to the same BMI value in a given person. Besides precluding the estimation of unambiguous causal effects, this violation of consistency affects the ability to address two additional conditions that are also necessary for causal inference: exchangeability and positivity. We conclude that consistency violations not only preclude the estimation of well-defined causal effects but also compromise our ability to estimate ill-defined causal effects.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Fatigue in patients receiving maintenance dialysis: a review of definitions, measures, and contributing factors.

            Fatigue is a debilitating symptom or side effect experienced by many patients on long-term dialysis therapy. Fatigue has a considerable effect on patient health-related quality of life and is viewed as being more important than survival by some patients. Renal providers face many challenges when attempting to reduce fatigue in dialysis patients. The lack of a reliable, valid, and sensitive fatigue scale complicates the accurate identification of this symptom. Symptoms of daytime sleepiness and depression overlap with fatigue, making it difficult to target specific therapies. Moreover, many chronic health conditions common in the long-term dialysis population may lead to the development of fatigue and contribute to the day-to-day and diurnal variation in fatigue in patients. Key to improving the assessment and treatment of fatigue is improving our understanding of potential mediators, as well as potential therapies. Cytokines have emerged as an important mediator of fatigue and have been studied extensively in patients with cancer-related fatigue. In addition, although erythropoietin-stimulating agents have been shown to mitigate fatigue, the recent controversy regarding erythropoietin-stimulating agent dosing in patients with chronic kidney disease suggests that erythropoietin-stimulating agent therapy may not serve as the sole therapy to improve fatigue in this population. In conclusion, fatigue is an important and often underrecognized symptom in the dialysis population. Possible interventions for minimizing fatigue in patients on long-term dialysis therapy should aim at improving health care provider awareness, developing improved methods of measurement, understanding the pathogenesis better, and managing known contributing factors.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials.

              Patient-reported outcomes (PROs), such as symptoms, health-related quality of life (HRQOL), or patient perceived health status, are reported directly by the patient and are powerful tools to inform patients, clinicians, and policy-makers about morbidity and 'patient suffering', especially in chronic diseases. Patient-reported outcomes provide information on the patient experience and can be the target of therapeutic intervention. Patient-reported outcomes can improve the quality of patient care by creating a holistic approach to clinical decision-making; however, PROs are not routinely used as key outcome measures in major cardiovascular clinical trials. Thus, limited information is available on the impact of cardiovascular therapeutics on PROs to guide patient-level clinical decision-making or policy-level decision-making. Cardiovascular clinical research should shift its focus to include PROs when evaluating the efficacy of therapeutic interventions, and PRO assessments should be scientifically rigorous. The European Society of Cardiology and other professional societies can take action to influence the uptake of PRO data in the research and clinical communities. This process of integrating PRO data into comprehensive efficacy evaluations will ultimately improve the quality of care for patients across the spectrum of cardiovascular disease.
                Bookmark

                Author and article information

                Contributors
                john.larkin@fmc-na.com
                Journal
                BMC Nephrol
                BMC Nephrol
                BMC Nephrology
                BioMed Central (London )
                1471-2369
                7 December 2020
                7 December 2020
                2020
                : 21
                : 529
                Affiliations
                [1 ]GRID grid.412522.2, ISNI 0000 0000 8601 0541, School of Medicine, , Pontifícia Universidade Católica do Paraná, ; Curitiba, PR Brazil
                [2 ]GRID grid.419076.d, ISNI 0000 0004 0603 5159, Global Medical Office, Fresenius Medical Care, ; 920 Winter Street, Waltham, MA 02451 USA
                [3 ]GRID grid.437493.e, ISNI 0000 0001 2323 588X, Research Division, , Renal Research Institute, ; New York, NY USA
                [4 ]GRID grid.133342.4, ISNI 0000 0004 1936 9676, University of California Santa Barbara, ; Santa Barbara, CA USA
                [5 ]GRID grid.59734.3c, ISNI 0000 0001 0670 2351, Icahn School of Medicine at Mount Sinai, ; New York, NY USA
                [6 ]GRID grid.452687.a, ISNI 0000 0004 0378 0997, Partners HealthCare, ; Boston, MA USA
                Author information
                http://orcid.org/0000-0001-8873-8971
                Article
                2187
                10.1186/s12882-020-02187-9
                7720452
                33287719
                7426caf8-4531-4b52-8949-1d6ca416dc7a
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 9 February 2020
                : 25 November 2020
                Funding
                Funded by: Fresenius Medical Care
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2020

                Nephrology
                dialysis recovery time,patient reported outcomes,health related quality of life,adequacy,intradialytic hypotension

                Comments

                Comment on this article